Lengo Therapeutics Appoints Diana Hausman as Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)-- Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Diana Hausman, M.D., as Chief Medical Officer. In this role, Dr. Hausman will be responsible for leading clinical development and strategy for the Company.
“Diana brings invaluable experience and expertise to our team, as we advance our pipeline of best-in-class precision therapeutics for treatment-resistant cancers,” said Helen Jenkins, Chief Executive Officer, Lengo Therapeutics. “Her experience leading several clinical programs in oncology from first in human through to registrational studies is incredibly relevant, as we prepare for our next stage of growth.”
“I am excited to join the incredible team at Lengo, and work alongside a world-class team of scientists and leaders in kinase inhibition developing transformative therapeutics in oncology,” said Dr. Hausman. “I look forward to leveraging my extensive clinical experience in the biotechnology industry to lead the continued development of Lengo’s pipeline for cancer patients with unmet medical needs.”
Dr. Diana Hausman is a board-certified medical oncologist with over 20 years of clinical drug development experience. Prior to joining Lengo, she served as Chief Medical Officer for Zymeworks Inc. for 5 years. While at Zymeworks, Dr. Hausman oversaw all aspects of clinical development, including advancement of the HER2-targeted biparatopic antibody zanidatamab from initial IND to ongoing global Phase 2 and pivotal studies, including breakthrough therapy designation for biliary tract cancer.
Dr. Hausman was previously CMO at Oncothyreon Inc where she oversaw the Phase 1b and early Phase 2 clinical program for the HER2-targeted small molecule, tucatinib. She has also held positions of increasing responsibility at ZymoGenetics, Berlex, and Immunex, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine and specialty training in hematology and medical oncology at the University of Washington. She received her M.D. degree from the University of Pennsylvania, Philadelphia, PA, and an A.B. in biology from Princeton University.
About Lengo Therapeutics
Lengo Therapeutics is a biopharmaceutical company committed to developing novel, precision medicines targeting driver mutations in oncology. Lengo has assembled a team of scientists and industry leaders with extensive expertise in kinase biology, covalent drug-target technology and oncology drug development. The company’s vision is to develop a pipeline of investigational candidates that can offer benefit to patients with cancers harboring driver mutations. Lengo Therapeutics is based in San Diego. For more information, please visit www.lengotx.com.
Source: Lengo Therapeutics